Email updates

Keep up to date with the latest news and content from Arthritis Research & Therapy and BioMed Central.

Open Access Research article

Potent anti-inflammatory and antinociceptive activity of the endothelin receptor antagonist bosentan in monoarthritic mice

Anne-Katja Imhof1, Laura Glück1, Mieczyslaw Gajda2, Rolf Bräuer2, Hans-Georg Schaible3 and Stefan Schulz1*

Author Affiliations

1 Institute of Pharmacology and Toxicology, University Hospital, Friedrich Schiller University, Drackendorfer Str. 1, 07747 Jena, Germany

2 Institute of Pathology, University Hospital, Friedrich Schiller University, Ziegelmühlenweg 1 07743 Jena, Germany

3 Institute of Physiology I, University Hospital, Friedrich Schiller University, Teichgraben 8, 07743 Jena, Germany

For all author emails, please log on.

Arthritis Research & Therapy 2011, 13:R97  doi:10.1186/ar3372

Published: 20 June 2011

Abstract

Introduction

Endothelins are involved in tissue inflammation, pain, edema and cell migration. Our genome-wide microarray analysis revealed that endothelin-1 (ET-1) and endothelin-2 (ET-2) showed a marked up-regulation in dorsal root ganglia during the acute phase of arthritis. We therefore examined the effects of endothelin receptor antagonists on the development of arthritis and inflammatory pain in monoarthritic mice.

Methods

Gene expression was examined in lumbar dorsal root ganglia two days after induction of antigen-induced arthritis (AIA) using mRNA microarray analysis. Effects of drug treatment were determined by repeated assessment of joint swelling, pain-related behavior, and histopathological manifestations during AIA.

Results

Daily oral administration of the mixed ETA and ETB endothelin receptor antagonist bosentan significantly attenuated knee joint swelling and inflammation to an extent that was comparable to dexamethasone. In addition, bosentan reduced inflammatory mechanical hyperalgesia. Chronic bosentan administration also inhibited joint swelling and protected against inflammation and joint destruction during AIA flare-up reactions. In contrast, the ETA-selective antagonist ambrisentan failed to promote any detectable antiinflammatory or antinociceptive activity.

Conclusions

Thus, the present study reveals a pivotal role for the endothelin system in the development of arthritis and arthritic pain. We show that endothelin receptor antagonists can effectively control inflammation, pain and joint destruction during the course of arthritis. Our findings suggest that the antiinflammatory and antinociceptive effects of bosentan are predominantly mediated via the ETB receptor.